OMICS International Conferences invites all the participants from all over the world to attend ‘Annual Congress on Rare Diseases Orphan Drugs’ during Oct 26-27, 2016 in Chicago, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Rare Diseases 2016 is a global platform to discuss and learn about Rare Diseases, rare cancer, Morgellons, Renal cell carcinoma, malignant glioma, Turner syndrome, Multiple myeloma, Hepatocellular carcinoma, Diabetes in the young, Systemic Amyloidosis, Autoimmune diseases, Disorders of genetic origin, idiopathic disorders, rare genetic diseases, Orphan Drugs, Alzheimer’s Disease and many more. OMICS International organizes a conference series of 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Why to attend?

In today's economic climate your business decisions are as crucial as ever. International conference on Rare Diseases and Orphan Drugs allow you to maximize your time and marketing dollars while receiving immediate feedback on your new products and services. International conference on Rare Diseases and Orphan Drugs is organizing an outstanding Scientific Exhibition/Program and anticipates the world's leading specialists involved Rare Diseases and Orphan Drugs. Your organization will benefit with excellent exposure to the leaders in Rare Diseases and Orphan Drugs. Rare Diseases-2016 is an exciting opportunity to showcase the new technology, the new products of your company, and/or the service your industry may offer to a broad international audience.

Target Audience

•   Super specialists
•   Specialists
•   Researchers
•   Students
•   Industrial delegates
•   Academia and Research
•   Biomedical companies
•   Healthcare Professionals

Summary

Rare Disease is a branch of medicine. Which are an important public health issue and challenge for the medical community. They are called “Health Orphan”. The term “Orphan Drug” refers to a drug or biologics such as vaccine or blood product that treats a rare disease or conditions. Rare Disease welcomes all the specialists and super specialists of medical field to discuss on rare diseases, diagnose and determine the severity of or treat a variety of diseases, including many types of rare cancers, Morgellons, Renal cell carcinoma, malignant glioma, Multiple myeloma, Hepatocellular carcinoma and other abnormalities within the body. This conference will witness the fusion of advanced technology in the field of Rare Diseases.

The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Rare Diseases-2016, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Rare Diseases-2016 organizing committee look forward to meet you in Chicago, USA.

For more details please visit: http://rarediseases.conferenceseries.com/

Importance and Scope

Rare Diseases-2016 will be the best platform for all the specialists and super specialists, renowned Scientists, research scholars, students who are working in this field across the globe under a single roof to exchange their knowledge related to Rare Diseases and Orphan Drugs. This international event is an effort to find an alternative for invasive imaging technique against diseases like rare cancer, Morgellons, Renal cell carcinoma, malignant glioma, Multiple myeloma, Hepatocellular carcinoma etc.

OMICS Group welcomes all the specialists and super specialists, research scholars, industrial professionals and student delegates from biomedical and healthcare sectors to be a part of the esteemed Rare Diseases-2016. It also catalyses for information exchange and networking between researchers and business entrepreneurs of diverse backgrounds for the advancement of Technology and Research in the field of Rare Diseases. As this will be the best amalgamation of academia and research involving every aspect of empirical and conceptual thinking in exploring new dimensions in this field. It is open to all types of research methodologies both from academia and industry.

Why Chicago?

Rare Diseases-2016 is going to held in Chicago, a city in the U.S. state of Illinois, is the third most populous city in the United States and the most populous city in the American Midwest, with approximately 2.7 million residents. Its metropolitan area (also called "Chicago land"), which extends into Indiana and Wisconsin, is the third-largest in the United States, after those of New York City and Los Angeles, with an estimated 9.8 million people. Chicago is the county seat of Cook County, though a small portion of the city limits also extends into Du Page County.

Chicago was incorporated as a city in 1837, near a portage between the Great Lakes and the Mississippi River watershed. Today, Chicago is listed as an alpha+ global city by the Globalization and World Cities Research Network, and ranks seventh in the world in the 2012 Global Cities Index. The city is an international hub for finance, commerce, industry, telecommunications, and transportation, with O'Hare International Airport being the second-busiest airport in the world in terms of traffic movements.

In 2012, Chicago hosted 46.2 million international and domestic visitors. Among metropolitan areas, Chicago has the fourth-largest gross domestic product (GDP) in the world, just behind Tokyo, New York City, and Los Angeles, and ranking ahead of London and Paris. Chicago is one of the most important Worldwide Centers of Commerce and trade.

Chicago's notability has found expression in numerous forms of popular culture, including novels, plays, films, and songs. The city has many nicknames, which reflect the impressions and opinions about historical and contemporary Chicago. The best-known include "Windy City" and "Second City. Rare Diseases-2016 Conference at Chicago will certainly give a wonderful experience to attendees to explore the beautiful city with gaining knowledge.

Conference Highlights

•   Different types of Rare Diseases
•   Clinical Research and Public Awareness
•   Mystery Diagnosis of Rare Diseases
•   Challenges in Rare Diseases Treatment
•   Orphan Drugs, Development trends and strategies
•   Orphan Drugs and Ethical Issues
•    Helping patients afford the high cost of orphan drugs-comparison with others
•    Future Hereditary and Rare Diseases e Prospects of Rare Diseases

Why to attend?

In today's economic climate your business decisions are as crucial as ever. International conference on Rare Diseases and Orphan Drugs allow you to maximize your time and marketing dollars while receiving immediate feedback on your new products and services. International conference on Rare Diseases and Orphan Drugs is organizing an outstanding Scientific Exhibition/Program and anticipates the world's leading specialists involved Rare Diseases and Orphan Drugs. Your organization will benefit with excellent exposure to the leaders in Rare Diseases and Orphan Drugs. Rare Diseases-2016 is an exciting opportunity to showcase the new technology, the new products of your company, and/or the service your industry may offer to a broad international audience.

A Unique Opportunity for Advertisers and Sponsors at this International event  http://rarediseases.conferenceseries.com/sponsors.php

Target Audience

Specialists and super specialists, researchers, students, industrial delegates from Academia and Research along with the industrial professionals from biomedical companies and healthcare sectors.

Hospitals Associated with Rare Diseases Research USA & Worldwide

• The Manton Center for Orphan Disease Research (Boston, USA)
• US hospital for rare disease research (USA)
• NORD (National Organization for Rare Disorders) (USA)
• Chicago Rare Disease Foundation (Chicago, USA)
• National Institute of Health (NIH) funds research consortia to study more than 200 rare diseases (USA)
• Children’s hospital of Pittsburgh (Center for Rare Disease Therapy) (USA)
• Boston Children’s Hospital (The Manton Center for Orphan Disease Research) (Boston, USA)
• Birmingham children’s Hospital (NHS Foundation Trust) (UK)
• The Children’s Hospital of Philadelphia (USA)
• Hospitals Associated with Rare Diseases Research Chicago
• Comer Children’s Hospital – University of Chicago
• Ann & Robert H. Lurie Children’s Hospital of Chicago

Major Associations Worldwide

• The Boler-Parseghian Center for Rare & Neglected Diseases
• Cystic Fibrosis Foundation
• European Union Committee of Experts on Rare Diseases
• Multiple Myeloma Research Foundation
• U.S. Food and Drug Administration
• RARE Foundation Alliance
• Birmingham children’s Hospital (NHS Foundation Trust)
• Japan Patient Association
• EURORDIS Rare Diseases Europe
• Royal Society of Medicine
• EveryLife Foundation for Rare Diseases
• Global Genes Allies in Rare Diseases
• Rare Diseases South Africa
• Short Bowel Syndrome Foundation
• Rare Diseases or Syndromes and Clinical Societies
• Rare Diseases Patient Association Funding
• Rare Disorders Society Singapore
• Guardian Hands Foundation
• IRDR Intractable & Rare Diseases Research (Europe)

Major Associations Chicago

• National Organization for Rare Diseases (NORD)
• Chicago Rare Disease Foundation
• The Boler-Parseghian Center for Rare & Neglected Diseases
• Alzheimer's Disease Organizations
• National Institute of Health
• Major Associations Worldwide
• Canadian Organization for Rare Diseases (CORD)
• National Alliances for Rare Diseases
• Organization for Rare Diseases India (ORDI)

Industries Associated with Rare Diseases Research Chicago

• AbbVie North Chicago
• Genus Oncology Vernon Hills
• Elorac Vernon Hills      
• Baxter International Deerfield
• ViroPharma
• Dohmen Life Science Services Acquires Chicago Company
• Astellas Pharma US Northbrook
• Lundbeck Deerfield
• Marathon Pharmaceuticals
• Industries Associated with Rare Diseases Research Worldwide
• Novartis (Switzerland)
• Pfizer (USA)
• Roche (Switzerland)
• Onyx Pharmaceuticals
• Amicus Therapeutics
• Sarepta Therapeutics
• Prosensa
• Sanofi (France)
• Merck & Co. (USA)
• Swedish Orphan Biovitrum AB
• Genzyme
• AstraZeneca (UK)
• GlaxoSmithKline
• Vertex Pharmaceuticals
• NPS Pharmaceuticals
• Shire
• Johnson & Johnson (USA)
• ViroPharma
• Sigma-Tau Pharmaceuticals
• ViroPharma
• European Medicines Agency
• Takeda (Japan)
• Aegerion Pharmaceuticals
• Novo Nordisk (Denmark)
• Cancer Prevention Pharmaceuticals
• Roche
• PharmaMar USA
• Raptor Therapeutics
• Daiichi Sankyo (Japan)
• Araim Pharmaceuticals
• Octapharma USA
• Gilead sciences (USA)
• Millennium Pharmaceuticals
• Actavis (USA)
• Amgen (USA)
• Glaxosmithkline (UK)
• Bayer HealthCare (Germany)

Top Universities in Chicago & USA

• University of California - San Francisco
• The University of Chicago Medicine
• The University of Chicago Celiac Disease Center
• University of Chicago (Neurofibromatosis Clinic)
• University Of Chicago Medical Center
• The University of Chicago Genetic Services
• University of Pennsylvania
• Northwestern University Feinberg School of Medicine
• Johns Hopkins University
• University of Pennsylvania

Top Universities in World Wide

• Harvard University
• Stanford University
• Washington University in St
• Yale University
• Columbia University
• University of Washington
• Duke University
• Top Universities Worldwide
• University of Oxford
• University of Cambridge
• Rare Genomics Institute
• GMEC, The Global Medical Excellence Cluster
• University of Zurich
• Cambridge University
• Yale University
• Emory University
• Karolinska University
• John Hopkins University
• Newcastle University
• University of Pittsburgh Study
• University of Valencia
• Osaka University
• McMaster University
• University of Celiac Disease Center
• Cincinnati Children's Hospital Medical Center
• Center for Rare Neurological Diseases (Northwestern University Feinberg School of Medicine)

Glance at Market analysis report

Summary GBI Research, the leading business intelligence provider, has released its latest research “Orphan Disease Therapeutics Market to 2018 – Improved Understanding of Rare Diseases’ Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation”, which provides insights into the orphan disease therapeutics market until 2018. It includes the geographical distribution of Fabry, Pompe, Mucopolysaccharidosis VI, Idiopathic Thrombocytopenic Purpura, Huntington’s disease and Ovarian cancer markets across the US, the top five countries of Europe and in Japan. The report provides competitive benchmarking for the leading companies and also analyses the mergers, acquisitions and licensing agreements that shape the global markets. GBI Research’s analysis shows that the overall global orphan disease therapeutics market is expected to grow at a significant compound annual growth rate (CAGR) of 13.1% from $2.3 billion 2010 to $6 billion in 2018 in the US, the top five countries of Europe and Japan. Increasing awareness of the disease and drugs among patients and physicians, patent protection and exclusivity of Nplate and Promacta for ITP market, anticipated launch of new molecules such as ACR-16, AMR-101 and HD-02 for the treatment of HD and the approval of Avastin for the treatment of advanced ovarian cancer in Europe will drive the global orphan disease therapeutics market in the forecast period.

The 2013 Orphan Drug Report from Evaluate, which launched today at the 2013 BIO international Convention, sheds light on the market dynamics of orphan drugs — pharmaceutical products aimed at rare diseases or disorders — projecting that sales will experience a compound annual growth rate of 7.4 percent between 2012 and 2018, nearly double that of the prescription drug market, excluding generics.  The report based on EvaluatePharma® data found that the worldwide orphan drug market is set to reach $127 billion by 2018, doubling that of the overall prescription drug market.

Market Growth of Rare Diseases Research

GBI Research’s analysis shows that the overall global orphan disease therapeutics market is expected to grow at a significant compound annual growth rate (CAGR) of 13.1% from $2.3 billion 2010 to $6 billion in 2018 in the US, the top five countries of Europe and Japan.

The 2013 Orphan Drug Report from Evaluate, which launched today at the 2013 BIO international Convention, sheds light on the market dynamics of orphan drugs — pharmaceutical products aimed at rare diseases or disorders — projecting that sales will experience a compound annual growth rate of 7.4 percent between 2012 and 2018, nearly double that of the prescription drug market, excluding generics.  The report based on Evaluate Pharma  data found that the worldwide orphan drug market is set to reach $127 billion by 2018, doubling that of the overall prescription drug market

The global orphan drugs market reached $84.9 billion in 2009 growing from $58.7 billion in 2006 from $54.5 billion in 2005.The market is expected to grow at a compound annual growth rate (CAGR) of nearly 6% to reach $112.1 billion by 2014.The U.S. accounted for 51% of the market in 2009 and is expected to grow at a CAGR of 8.9% to reach $65.9 billion by 2014.By 2020, orphan drugs will own 19% of the total share of prescription drug sale excluding generics, reaching a whopping $176 billion in annual sales, according to Andreas Hadjivasiliou, an analyst with Evaluatepharma.

Fund Allotment to Rare diseases Research

Since 1989, NORD’s research grants have resulted in at least two FDA-approved products and the publication of numerous significant journal articles. Our more than 100 disease-specific research funds are supported primarily by patients and patient organizations.  Industry support is welcome and would demonstrate commitment to the study of diseases for which there are few-if any- other sources of funding.

NORD's Research Program provides seed money grants to academic scientists for clinical studies related to the development of diagnostics or treatments of rare diseases. Requests for proposals are posted once a year in the late winter or early spring. NORD's Research Program also includes the NORD/Roscoe Brady Lysosomal Storage Diseases Fellowships.

Physician scientists at 22 consortia will collaborate with representatives of 98 patient advocacy groups to advance clinical research and investigate new treatments for patients with rare diseases. The collaborations are made possible through awards by the National Institutes of Health — totalling about $29 million in fiscal year 2014 funding — to expand the Rare Diseases Clinical Research Network (RDCRN), which is led by NIH’s National Center for Advancing Translational Sciences (NCATS).

References

http://www.raredisorders.ca/index.html

http://www.newshd.net/senza-categoria/1115/orphan-disease-therapeutics-market-to-2018-improved-understanding-of-rare-diseases-heterogeneity-and-novel-new-clinical-trial-designs-to-foster-innovation/

http://www.biotech-now.org/health/2013/04/worldwide-orphan-drug-market-to-grow-to-127-billion-by-2018

http://www.topuniversities.com/university-rankings/university-subject-rankings/2014/medicine#sorting=rank+region=+country=+faculty=+stars=false+search=

http://www.huffingtonpost.com/2014/03/11/best-medical-schools-2015_n_4935490.html?ir=India&adsSiteOverride=in

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996062/

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996062/

http://www.mmm-online.com/features/therapeutic-focus-rare-diseases/article/394333/